Hitachi Vantara names ex-Cognizant executive Gajen Kandiah as CEO - San Francisco News
by Maria Thomas
Updated Jul 01, 2020
Kandiah will replace Toshiaki Tokunaga, current CEO and chairman of the Board. Tokunaga will remain as chairman, said the company.
"The opportunity to lead Hitachi Vantara is a thrilling one. I am confident that if we align our broad portfolio of data storage, analytics, industry-specific solutions and IT services behind a singular vision to delight our clients, we will become a true digital leader," Kandiah said in a statement late Tuesday.
During 15 years with Cognizant, he helped grow the company from $368 million in annual revenues to more than $16 billion.
He was most recently president of Cognizant's multi-billion-dollar digital business, a role in which he led the acquisitions of software engineering company Softvision, marketing solutions provider Netcentric, and Idea Couture, a digital innovation and technology services company.
"Thanks to strong internal development, strategic acquisitions, and the integration with Hitachi Consulting, we have added the capabilities we need to guide our customers from what's now to what's next. Kandiah has an impressive track record in rapidly scaling digital businesses," said Tokunaga.
Before joining Cognizant, Kandiah co-founded NerveWire, a venture capital-backed management consulting and systems integration firm, which was later acquired by Wipro.
Related Articles
- Optical Illusion Brain Test: If you have Sharp Eyes Find the Number 442 in 20 Secs
- London-based firm Nothing to release its Phone (2)
- Covid will continue to cause mini-waves, not become seasonal yet: Scientists
- Hackers offering crypto accounts for as low as $30 on darknet
- Reddit's new feature to allow users to share its content on other platforms
- Surgical masks can help kids fight respiratory infections: Study
- LinkedIn's new AI feature to write messages to hiring team
- Microsoft introduces Xbox Game Pass' new Friend Referral programme
- Disbursed over Rs 31 cr in claims to delivery partners in FY22-23: Swiggy
- India emerging as favourable destination for clinical trials: Report